Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VTVT

vTv Therapeutics Inc

Nov 14 • 04:00PM ET

30.80

-0.47 -1.50 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX AMGN GILD BIIB INCY NBIX IONS RGEN PTCT

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.32	Insider Own	28.66%	Shs Outstand	3.94M	Perf Week	18.37%
Market Cap	128.72M	Forward P/E	-	EPS next Y	-3.50	Insider Trans	0.00%	Shs Float	2.81M	Perf Month	37.44%
Enterprise Value	30.58M	PEG	-	EPS next Q	-0.89	Inst Own	20.63%	Short Float	0.69%	Perf Quarter	99.05%
Income	-23.47M	P/S	6435.79	EPS this Y	-12.50%	Inst Trans	16.48%	Short Ratio	3.52	Perf Half Y	50.17%
Sales	0.02M	P/B	1.72	EPS next Y	2.64%	ROA	-32.90%	Short Interest	0.02M	Perf YTD	123.05%
Book/sh	17.91	P/C	1.31	EPS next 5Y	-4.10%	ROE	-54.87%	52W High	33.06 -6.84%	Perf Year	107.13%
Cash/sh	23.57	P/FCF	-	EPS past 3/5Y	27.95% 32.98%	ROIC	-33.27%	52W Low	13.15 134.22%	Perf 3Y	-6.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-36.68% -18.12%	Gross Margin	-111.76%	Volatility	9.69% 7.70%	Perf 5Y	-53.89%
Dividend TTM	-	EV/Sales	1528.79	EPS Y/Y TTM	26.62%	Oper. Margin	-175382.35%	ATR (14)	2.04	Perf 10Y	-90.52%
Dividend Ex-Date	-	Quick Ratio	9.79	Sales Y/Y TTM	-98.30%	Profit Margin	-138058.82%	RSI (14)	79.51	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.79	EPS Q/Q	-23.17%	SMA20	27.41%	Beta	0.42	Target Price	35.50
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	36.00%	Rel Volume	2.77	Prev Close	31.27
Employees	23	LT Debt/Eq	0.00	Earnings	Nov 06 AMC	SMA200	65.40%	Avg Volume	5.54K	Price	30.80
IPO	Jul 30, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	-10.20% -	Trades		Volume	15,308	Change	-1.50%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-19	Initiated	H.C. Wainwright	Buy
Apr-10-18	Downgrade	Stifel	Buy → Hold	$12 → $1
Mar-08-18	Initiated	ROTH Capital	Buy	$17
Feb-08-18	Initiated	Northland Capital	Outperform	$28
Sep-26-16	Initiated	H.C. Wainwright	Buy	$13
Sep-04-15	Initiated	Canaccord Genuity	Buy	$15
Aug-24-15	Initiated	Stifel	Buy	$17
Aug-24-15	Initiated	Piper Jaffray	Overweight	$24

Nov-11-25 12:00PM	All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy (Zacks)
Nov-06-25 05:42PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +5.07%
04:15PM	vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-09-25 08:00AM	vTv Therapeutics Announces New Appointments to its Scientific Advisory Board (GlobeNewswire)
Sep-15-25 08:00AM	vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting (GlobeNewswire)
04:57PM	Loading…
Sep-03-25 04:57PM	UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
08:00AM	vTv Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Sep-02-25 08:00AM	vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund (GlobeNewswire) +13.30%
Aug-12-25 04:53PM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.35%
04:15PM	vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 08:00AM	vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin (GlobeNewswire) +10.52%
Aug-07-25 08:00AM	vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes (GlobeNewswire)
Jun-11-25 08:00AM	vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire)
May-19-25 09:00AM	vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin (GlobeNewswire)
May-15-25 04:19PM	VTv Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +5.16% -6.16%
04:01PM	Loading…
04:01PM	vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
12:00PM	vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes (GlobeNewswire)
Mar-21-25 04:46AM	The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics (Zacks) -5.48%
Mar-20-25 06:00PM	VTv Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
05:35PM	vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update (GlobeNewswire)
12:45PM	Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More (Zacks)
Mar-18-25 11:06AM	FDA removes hold on vTvs cadisegliatin clinical programme for diabetes (Clinical Trials Arena) -7.70%
Mar-17-25 12:40PM	vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial (GuruFocus.com) +53.13%
11:46AM	FDA Lifts Clinical Hold-vTv Stock Jumps Nearly 28% on Diabetes Drug Progress (GuruFocus.com)
08:30AM	vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes (GlobeNewswire)
Dec-09-24 07:33AM	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER (PR Newswire)
Dec-02-24 04:05PM	vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 05:04PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +7.58% +7.12%
04:05PM	vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-26-24 05:01PM	vTv Therapeutics Faces License Agreement Termination (TipRanks)
05:26PM	Loading…
Aug-08-24 05:26PM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-24 11:23AM	FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks (Benzinga) -24.53%
06:53AM	FDA places vTv Therapeuticss cadisegliatin programme on clinical hold (Clinical Trials Arena)
Jul-26-24 04:05PM	vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold (GlobeNewswire)
Jun-24-24 04:05PM	vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes (GlobeNewswire)
May-28-24 08:00AM	CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING (PR Newswire) -11.04%
May-20-24 12:00PM	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER (PR Newswire)
May-09-24 10:57PM	VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024 (InvestorPlace) +5.22%
05:02PM	VTv Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:51PM	vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-24 08:30AM	CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT (PR Newswire)
Mar-13-24 08:24AM	VTv Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-04-24 03:49PM	The Top 3 Healthcare Stocks to Buy on Weakness in 2024 (InvestorPlace) -15.35%
08:00AM	vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes (GlobeNewswire)
Mar-01-24 08:00AM	vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire) -5.70%
Feb-28-24 08:00AM	vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund (GlobeNewswire) +95.88%
Feb-22-24 04:00PM	CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE (PR Newswire)
Nov-09-23 05:06PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -6.82%
04:30PM	vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-23 08:00AM	vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference (GlobeNewswire)
Nov-02-23 08:00AM	vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-01-23 08:00AM	vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million (GlobeNewswire)
Sep-27-23 08:30AM	CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 (PR Newswire)
Sep-26-23 08:30AM	Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer (PR Newswire)
Sep-22-23 05:22AM	3 Tumbling Stocks to Take a Chance On Now (InvestorPlace)
Sep-18-23 08:30AM	CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA (PR Newswire)
Aug-24-23 12:35PM	Is vTv Therapeutics Inc (VTVT) Modestly Undervalued? (GuruFocus.com) -20.58%
Aug-16-23 02:44PM	vTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on Nasdaq (American City Business Journals)
Aug-11-23 04:37PM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-10-23 08:33AM	Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer (PR Newswire) +8.63%
Jun-16-23 08:00AM	vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline (GlobeNewswire) +5.21%
Jun-15-23 07:33AM	CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON (PR Newswire)
May-24-23 09:00AM	vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals (GlobeNewswire)
May-12-23 08:11AM	vTv Therapeutics Insider Ups Holding During Year \ (Simply Wall St.) -5.55%
May-11-23 04:33PM	VTv Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:15PM	vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-20-23 08:00AM	Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 (PR Newswire)
Mar-30-23 08:31AM	Is vTv Therapeutics (NASDAQ:VTVT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-17-23 01:01PM	3 Pharma Stocks That Could Benefit from Global Healthcare Trends (InvestorPlace)
Mar-06-23 06:11PM	VTv Therapeutics: Q4 Earnings Snapshot (AP Finance) +16.32%
05:56PM	vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update (GlobeNewswire)
08:02AM	Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases (PR Newswire)
Mar-03-23 05:06AM	vTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 88% if they invested five years ago (Simply Wall St.)
Feb-27-23 08:02AM	Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma (PR Newswire)
Feb-01-23 05:00PM	Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics (GlobeNewswire)
Jan-20-23 09:03AM	Private equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last week (Simply Wall St.)
Jan-09-23 08:00AM	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA (PR Newswire)
Dec-22-22 06:00AM	7 Drug Stocks That Will Soar in 2023 (InvestorPlace)
Dec-13-22 08:15AM	vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer (GlobeNewswire) -11.36%
Dec-03-22 07:04AM	Trade Alert: The Independent Director Of vTv Therapeutics Inc. (NASDAQ:VTVT), John Fry, Has Just Spent US$51k Buying A Few More Shares (Simply Wall St.)
Nov-15-22 02:46PM	Three months after leadership change, vTv Therapeutics reports cash of $15.3 million and net loss of $4.3 million in Q3 (American City Business Journals)
Nov-10-22 06:45PM	VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:25PM	vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 07:26AM	Paul Sekhri, new CEO of vTv Therapeutics, touts potential for diabetes drug as he looks to turn biotech around (American City Business Journals)
Sep-23-22 07:04AM	vTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year losses to 84% (Simply Wall St.) -6.39%
Aug-19-22 12:42PM	This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says (Benzinga)
Aug-18-22 06:41AM	After third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 million net loss in Q2 (American City Business Journals) -5.43%
Aug-15-22 06:43PM	vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +6.20% -11.68%
Aug-13-22 08:25AM	What You Need To Know About vTv Therapeutics Inc.'s (NASDAQ:VTVT) Investor Composition (Simply Wall St.)
Aug-09-22 06:09AM	Months after celebrating its first exit, CinRx invests $10M in newest portfolio company (American City Business Journals)
Jul-27-22 03:01PM	vTv Therapeutics appoints Paul Sehkri as new president and CEO (American City Business Journals)
07:00AM	vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer (GlobeNewswire)
Jul-25-22 08:22AM	vTv Therapeutics Shares Jump On Equity Investment (Benzinga)
07:00AM	vTv Therapeutics Announces Investment by CinRx Pharma (GlobeNewswire)
Jun-04-22 11:00AM	vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes (GlobeNewswire)
Jun-01-22 06:54AM	vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare (GlobeNewswire) +30.62%
May-19-22 06:40AM	3 Oversold Biotech Stocks to Buy Now (InvestorPlace) +12.72%

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STEVEN TUCH	Officer	May 01 '25	Proposed Sale	20.00	1,258	25,160		May 01 04:28 PM
STEVEN TUCH	Officer	Apr 29 '25	Proposed Sale	21.50	1,000	21,500		Apr 29 05:04 PM
STEVEN TUCH	Officer	Apr 24 '25	Proposed Sale	21.50	1,000	21,500		Apr 24 04:08 PM
SEKHRI PAUL J	Pres, CEO and Exec Chairperson	Nov 15 '24	Buy	16.65	3,156	52,543	3,156	Nov 19 04:31 PM
SEKHRI PAUL J	Pres, CEO and Exec Chairperson	Nov 18 '24	Buy	16.96	1,844	31,269	5,000	Nov 19 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTVT

vTv Therapeutics Inc

Upgrade your FINVIZ experience